Clinical trials: Smouldering Myeloma
Smoldering Multiple Myeloma
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment.
- Trial name
- NCT06365060
- Where
- 13 sites in United States
- Volunteers
- 400 people
- Sponsor
- Tufts Medical Center
Smoldering Plasma Cell Myeloma
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients.
- Trial name
- NCT04776395
- Testing
- Dexamethasone, Iberdomide Hydrochloride, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Emory University
High Risk Smoldering Multiple Myeloma (HR-SMM)
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who are at a High Risk (HR) of…
- Trial name
- LINKER-SMM2 (NCT07393282)
- Testing
- Linvoseltamab, Daratumumab
- Where
- 33 sites in United States, France and 4 more
- Volunteers
- 270 people
- Sponsor
- Regeneron Pharmaceuticals
Smoldering Multiple Myeloma
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: Lenalidomide Citarinostat (CC-96241) PVX-410
- Trial name
- NCT02886065
- Testing
- Hiltonol, Citarinostat, Lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.
- Trial name
- REVIVE (NCT06100237)
- Testing
- Teclistamab, Talquetamab, Daratumumab SC
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Carl Ola Landgren, MD, PhD
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
Escalating doses of Omega 3 Fatty Acids are being used in patients who have early stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS), or Smoldering Multiple Myeloma (SMM), whose…
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, Chronic Lymphocytic Leukemia
- Trial name
- NCT00899353
- Testing
- Omega 3 Fatty Acid
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Marshall University
High Risk Smoldering Multiple Myeloma
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
The purpose of this research study is to test whether the drug ibrutinib (trademark name: IMBRUVICA®) is effective at preventing the development of multiple myeloma in people who currently have smoldering myeloma.
- Trial name
- NCT02943473
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood.
- Conditions
- Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, Hematological Malignancies, B-cell Malignancy, Low-grade
- Trial name
- NCT02269592
- Where
- 7 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- Dana-Farber Cancer Institute
Pre-cancerous Lymphoproliferative Disorders
Oxford Pre-cancerous Lymphoproliferative Disorders Study
OxPLoreD is an observational cohort study to identify clinical, genomic and immunological predictive markers of progression to malignant disease.
- Trial name
- OxPLoreD (NCT04023747)
- Where
- 17 sites in United Kingdom
- Volunteers
- 574 people
- Sponsor
- University of Oxford
Smoldering Multiple Myeloma
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical…
- Trial name
- NCT05597345
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Rochester
Multiple Myeloma, High Risk Smoldering Multiple Myeloma
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
The purpose of this study is to see what effects, good and/or bad, the combination of ixazomib and dexamethasone has on the patient and the smoldering multiple myeloma.
- Trial name
- NCT02697383
- Testing
- Ixazomib (MLN9708), Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myeloma
A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
This study proposes to determine the clinical activity of this agent in patients with asymptomatic multiple myeloma. It is believed that TBL12 will help delay the onset of active multiple myeloma, with very few-if any- side…
- Trial name
- NCT01302366
- Testing
- TBL12
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health